AIM: To compare therapeutic efficacy and safety of ingavirin and arbidol in patients with influenza. MATERIAL AND METHODS: The trial included 105 patients with a verified diagnosis of influenza, definite clinical symptoms, body temperature at least 38 degrees C and duration of the disease 36 hours maximum. Ingavirin efficacy was analysed basing on the evidence for 100 patients with uncomplicated influenza. The patients were randomized into three groups: taking ingavirin in a single daily dose 90 mg (n = 33), placebo (n = 36) or arbidol (200 mg 4 times a day). The duration of the treatment was 5 days. RESULTS: Intake of ingavirin in initial 24-36 hours of the disease significantly reduced fever compared to placebo and arbidol (34.5, 72.0 and 48.4 hours, respectively). Ingavirin was less toxic and had no side effects. CONCLUSION:Ingavirin is safe and effective in the treatment of influenza. By some criteria it is more effective than arbidol.
RCT Entities:
AIM: To compare therapeutic efficacy and safety of ingavirin and arbidol in patients with influenza. MATERIAL AND METHODS: The trial included 105 patients with a verified diagnosis of influenza, definite clinical symptoms, body temperature at least 38 degrees C and duration of the disease 36 hours maximum. Ingavirin efficacy was analysed basing on the evidence for 100 patients with uncomplicated influenza. The patients were randomized into three groups: taking ingavirin in a single daily dose 90 mg (n = 33), placebo (n = 36) or arbidol (200 mg 4 times a day). The duration of the treatment was 5 days. RESULTS: Intake of ingavirin in initial 24-36 hours of the disease significantly reduced fever compared to placebo and arbidol (34.5, 72.0 and 48.4 hours, respectively). Ingavirin was less toxic and had no side effects. CONCLUSION:Ingavirin is safe and effective in the treatment of influenza. By some criteria it is more effective than arbidol.
Authors: Vladimir V Zarubaev; Angelica V Garshinina; Nelly A Kalinina; Anna A Shtro; Svetlana V Belyaevskaya; Alexander V Slita; Vladimir E Nebolsin; Oleg I Kiselev Journal: Pharmaceuticals (Basel) Date: 2011-11-25